This application seeks funding to purchase a HistoIndex Genesis®200 Platform – which represents the world’s first quantitative, fully-automated, stain-free, multi-organ, 2D & 3D multiphoton imaging system for tissue diagnostics, and which will provide the technology capable of more efficient and effective diagnosis leading to more personalised treatment strategies. The now commercially available Genesis® 200 is designed to assist in both preclinical and clinical research, by providing specific morphological and extracellular matrix analysis as well as quantification for the accurate study of the progression of the disease. Using laser and second harmonics technology, Genesis® 200 is able to detect any marginal improvement in treatment efficacy which is currently not available to pathologists with existing stain-based imaging techniques.
|Short title||HistoIndex Genesis Platform|
|Effective start/end date||3/02/17 → 31/12/17|